<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389646</url>
  </required_header>
  <id_info>
    <org_study_id>RAI2017</org_study_id>
    <nct_id>NCT03389646</nct_id>
  </id_info>
  <brief_title>CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)</brief_title>
  <official_title>CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Galeazzi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Galeazzi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multicentre, prospective cohort, observational clinical trial with a&#xD;
      retrospective control group to evaluate the effectiveness and safety of CERAMENTTM| G or V&#xD;
      used for filling of bone defects in the tibia and / or femur shaft and/or acetabulum in&#xD;
      patients scheduled for two-stage hip or knee prosthesis re-implantation for PJI or aseptic&#xD;
      loosening.&#xD;
&#xD;
      The results will be compared to a cohort of patients, which have been treated before the&#xD;
      introduction of CERAMENTTM|G or V for the same indication.&#xD;
&#xD;
      Due to the observational character of the study, there will be no patient randomization and&#xD;
      the clinicians in the study will remain entirely free to decide on the treatment of the&#xD;
      patients according to established clinical practice.&#xD;
&#xD;
      Only patients for whom therapeutic strategy for the use of the product for filling bone&#xD;
      defects is already planned according to local clinical practice, at the time of informed&#xD;
      consent form signature, will be enrolled in this study. Thus, the decision for the choice of&#xD;
      the surgical treatment, will not be influenced by the inclusion of the patient in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">September 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 27, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective with retrospective matched controls.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of post-surgical infection</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Hip Prosthesis Infection</condition>
  <condition>Knee Prosthesis Infection</condition>
  <arm_group>
    <arm_group_label>Treated with Device: Including sham</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control without CERAMENT device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CERAMENT G V</intervention_name>
    <description>During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU).</description>
    <arm_group_label>Treated with Device: Including sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to any study related procedure.&#xD;
&#xD;
          2. Male or female age ≥ 18 and ≤ 85 years.&#xD;
&#xD;
          3. Patients diagnosed with aseptic prosthetic loosening and scheduled for a one-stage hip&#xD;
             or knee cementless or hybrid revision prosthesis implantation&#xD;
&#xD;
          4. Patients with an interval spacer and scheduled for hip or knee cementless or hybrid&#xD;
             revision prosthesis implantation.&#xD;
&#xD;
          5. For those patients with an interval spacer, previous infection caused by&#xD;
             microorganism(s) sensitive to gentamicin or vancomycin.&#xD;
&#xD;
          6. Able (in the Investigators opinion) and willing to comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to give written informed consent.&#xD;
&#xD;
          2. Medically unfit for operative intervention.&#xD;
&#xD;
          3. Soft-tissue defects that prevent direct skin closure at revision surgery.&#xD;
&#xD;
          4. Females who are pregnant or lactating.&#xD;
&#xD;
          5. Females of child bearing potential and not taking adequate contraceptive precautions&#xD;
             are excluded from the trial. Females of child bearing potential taking acceptable&#xD;
             contraceptive precautions may be included.&#xD;
&#xD;
          6. Known allergy to gentamicin or vancomycin (or related antibiotics).&#xD;
&#xD;
          7. Patients with previous nephro- or ototoxicity events due to aminoglycoside and/or&#xD;
             vancomycin (or glycopeptides) use.&#xD;
&#xD;
          8. Presence of relevant contraindications as described in the EU CE mark Instructions for&#xD;
             Use (IFU).&#xD;
&#xD;
          9. Myasthenia gravis.&#xD;
&#xD;
         10. Need of a fully cemented joint prosthesis.&#xD;
&#xD;
         11. Psychiatric or neurological disorders.&#xD;
&#xD;
         12. Active infection at the site of surgery as diagnosed by clinical and/or laboratory&#xD;
             and/or imaging investigations.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CARLO L ROMANO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS GALEAZZI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CARLO L ROMANO, MD</last_name>
    <phone>+39026621441</phone>
    <phone_ext>907</phone_ext>
    <email>carlo.romano@grupposandonato.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NICOLA LOGOLUSO, MD</last_name>
    <phone>+39026621441</phone>
    <phone_ext>903</phone_ext>
    <email>nicola.logoluso@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Irccs Galeazzi</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CARLO L ROMANO, MD</last_name>
      <phone>+39026621441</phone>
      <phone_ext>907</phone_ext>
      <email>carlo.romano@grupposandonato.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

